Table 2.
Disease course after allo-SCT.
| Group A (HLA-Mismatched n = 39) | Group B (HLA-Matched n = 27) | ||||||
|---|---|---|---|---|---|---|---|
| Number | Fraction | Number | Fraction | p value | |||
| Outcome | |||||||
| Engraftment | |||||||
| Primary | 36 | 92% | 27 | 100% | |||
| Secondary | 3 | 8% | 0 | 0 | n.s. | ||
| aGvHD | |||||||
| None or grade I | 25 | 64% | 14 | 52% | n.s. | ||
| Grade II | 5 | 13% | 11 | 41% | n.s. | ||
| Grade III | 9 | 23% | 1 | 4% | n.s. | ||
| Grade IV | 0 | 0% | 1 | 4% | n.s. | ||
| cGvHD | |||||||
| None | 26 | 67% | 10 | 37% | n.s. | ||
| Limited | 6 | 15% | 7 | 26% | n.s. | ||
| Extensive | 1 | 3% | 2 | 7% | n.s. | ||
| N.A. due to death or last FU ≤ d100 | 5 | 13% | 7 | 26% | n.s. | ||
| Data not available | 1 | 3% | 1 | 4% | n.s | ||
| Outcome | |||||||
| DOC | 1 | 3% | 1 | 4% | n.s | ||
| DOD | 32 | 82% | 20 | 74% | n.s | ||
| Alive at last FU | 6 | 15% | 6 | 22% | n.s. | ||
| 2 Years EFS | 20% | 20% | n.s. | ||||
| Median EFS (months after allo-SCT) | |||||||
| Median | 7.5 | 5 | n.s. | ||||
| Median OS (months after allo-SCT) | |||||||
| Median | 8 | 6 | 0.04 | ||||
aGvHD/cGvHD acute/chronic graft versus host disease, OS overall survival, DOC death of complications, DOD death of disease, FU follow-up, allo-SCT allogeneic stem cell transplantation, N.a. not assessable, n.s. not significant.